Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 10, 2026
- Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share.
- 10-Q report · filed Nov 10, 2026
- Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million.
The audio replay and transcript follow the call.